Molsidomine - CAS 25717-80-0
Category:
APIs
Product Name:
Molsidomine
Catalog Number:
25717-80-0
Synonyms:
(1E)-1-ethoxy-N-(3-morpholin-4-yloxadiazol-3-ium-5-yl)methanimidate 1A Brand of Molsidomine Alpharma Brand of Molsidomine Aventis Brand of Molsidomine Azupharma Brand of Molsidomine betapharm Brand of Molsidomine Corpea Corvaton ct Arzneimittel Brand of M
CAS Number:
25717-80-0
Description:
Molsidomine,as an antianginal agent, is a long-lasting, orally active NO releasing vasodilator. It requires hepatic metabolism to be active, but causes no pharmacological tolerance.
Molecular Weight:
242.23
Molecular Formula:
C9H14N4O4
COA:
Inquire
MSDS:
Inquire
Canonical SMILES:
CCOC(=NC1=C[N+](=NO1)N2CCOCC2)[O-]
InChI:
1S/C9H14N4O4/c1-2-16-9(14)10-8-7-13(11-17-8)12-3-5-15-6-4-12/h7H,2-6H2,1H3
InChIKey:
XLFWDASMENKTKL-UHFFFAOYSA-N
Chemical Structure
CAS 25717-80-0 Molsidomine

Related Products


CAS 110-91-8 Morpholine

Morpholine
(CAS: 110-91-8)

Reference Reading


1.The nitric oxide donor molsidomine induces anxiolytic-like behaviour in two different rat models of anxiety.
Kalouda T1, Pitsikas N2. Pharmacol Biochem Behav. 2015 Nov;138:111-6. doi: 10.1016/j.pbb.2015.09.004. Epub 2015 Sep 9.
Experimental evidence indicates the implication of the nitric oxide (NO) in anxiety. Contradictory results were reported however, concerning the effects of NO donors in animal models of anxiety disorders. The present study investigated the effects of the NO donor molsidomine on anxiety-like behaviour and compared them with the anxiolytic diazepam in rats. For this purpose, the light/dark and the open field tests were used. The effects of molsidomine on motility were also assessed. Intraperitoneal (i.p.) administration of molsidomine (1 and 4mg/kg) did not influence rats' performance either in the light/dark or in the open field test. Administration of 2mg/kg molsidomine significantly prolonged the time spent in the light chamber in the rats compared with the vehicle-treated animals, did not affect the first latency to enter the dark chamber and did not influence the number of transitions between the light and dark compartments of the apparatus.
2.Molsidomine for the prevention of vasospasm-related delayed ischemic neurological deficits and delayed brain infarction and the improvement of clinical outcome after subarachnoid hemorrhage: a single-center clinical observational study.
Ehlert A1, Schmidt C2, Wölfer J3, Manthei G1, Jacobs AH4, Brüning R5, Heindel W6, Ringelstein EB7, Stummer W3, Pluta RM8, Hesselmann V6,9. J Neurosurg. 2016 Jan;124(1):51-8. doi: 10.3171/2014.12.JNS13846. Epub 2015 Jul 10.
OBJECT Delayed ischemic neurological deficits (DINDs) and cerebral vasospasm (CVS) are responsible fora poor outcome in patients with aneurysmal subarachnoid hemorrhage (SAH), most likely because of a decreased availability of nitric oxide (NO) in the cerebral microcirculation. In this study, the authors examined the effects of treatment with the NO donor molsidomine with regard to decreasing the incidence of spasm-related delayed brain infarctions and improving clinical outcome in patients with SAH. METHODS Seventy-four patients with spontaneous aneurysmal SAH were included in this post hoc analysis. Twenty-nine patients with SAH and proven CVS received molsidomine in addition to oral or intravenous nimodipine. Control groups consisted of 25 SAH patients with proven vasospasm and 20 SAH patients without. These patients received nimodipine therapy alone. Cranial computed tomography (CCT) before and after treatment was analyzed for CVS-related infarcts.
3.Protective Effects of Molsidomine Against Cisplatin-Induced Nephrotoxicity.
Karakoc HT1, Altintas R2, Parlakpinar H3, Polat A4, Samdanci E5, Sagir M3, Duran ZR4. Adv Clin Exp Med. 2015 Jul-Aug;24(4):585-93. doi: 10.17219/acem/47742.
BACKGROUND: Cisplatin, an effective chemotherapeutic agent, is used for the treatment of several types of cancers. However, cisplatin has some severe side effects such as nephrotoxicity. On the other hand, molsidomine, a NO donor, has anti-oxidative and vasodilator effects.
4.Comparative study of bacterial translocation control with nitric oxide donors and COX2 inhibitor.
García-Cenador MB1, Lorenzo-Gómez MF1, García-Moro M2, García-García MI3, Sánchez-Conde MP1, García-Criado FJ1, García-Sánchez E3, Lozano-Sánchez F1, García-Sánchez JE4. Enferm Infecc Microbiol Clin. 2016 Jan 29. pii: S0213-005X(15)00441-3. doi: 10.1016/j.eimc.2015.11.005. [Epub ahead of print]
OBJECTIVE AND DESIGN: To evaluate the beneficial effects of exogenous NO and an inhibitor of the COX2, and their action levels in a model of SIRS/bacterial translocation (BT) induced by Zymosan A®.